News & Events

GeneCentric Therapeutics Announces Presentations at Upcoming American Society of Clinical Oncology (ASCO) Annual Meeting

Ongoing Collaboration with Basilea Pharmaceutica International Ltd and their Lisavanbulin Clinical Program in Glioblastoma Will Be Highlighted at ASCO DURHAM, NC / ACCESSWIRE / June 2, 2021 / GeneCentric Therapeutics, a company making precision medicine more precise, today announced upcoming data presentations at the American Society of Clinical Oncology (ASCO) annual meeting, being held virtually […]

GeneCentric Therapeutics Announces New US Patent Granted for Molecular Characterization of Non-Squamous Non-Small Cell Lung Cancer

Patent Provides Framework for Further Development of Novel Lung Cancer Molecular Diagnostic Tests DURHAM, NC / ACCESSWIRE / March 9, 2021 / GeneCentric Therapeutics, a company making precision medicine more precise, announced today the granting of Patent No. 10,934,595 by the United States Patent and Trademark Office (USPTO), protecting another one of its novel RNA-based lung […]

GeneCentric Therapeutics Announces the Appointment of Philippe Chemla, PhD, MBA, as Chief Business Officer

Durham, NC, February 3, 2021 – GeneCentric Therapeutics, a company making precision medicine more precise, announced today the appointment of Philippe Chemla, PhD, MBA,  as Chief Business Officer.  Dr. Chemla has extensive experience across multiple areas of life sciences research and development, with a focus on strategic collaborations and business development. “Philippe brings a strong […]

GeneCentric Therapeutics Enters into Research Collaboration with Janssen on Genomic Drug Response Biomarkers for Non-Muscle Invasive Bladder Cancer

RNA-based investigation builds on prior bladder cancer research Durham, NC, August 12, 2020 – GeneCentric Therapeutics today announced it has entered into a research collaboration with Janssen Research & Development, LLC (Janssen) around RNA-based drug response biomarkers for non-muscle invasive bladder cancer (NMIBC). The research will involve the application of GeneCentric’s advanced RNA-based molecular profiling platform […]

GeneCentric Therapeutics and Erasmus University Medical Center Enter Bladder Cancer Research Collaboration

Research to focus on potential biomarkers of disease progression, immune and treatment response in the setting of Non-Muscle Invasive Bladder Cancer DURHAM, N.C., USA and ROTTERDAM, THE NETHERLANDS, August 5, 2020 — GeneCentric Therapeutics, Inc. and Erasmus University Medical Center (EUMC) today announced that they have entered into a research collaboration to identify RNA-based drug […]

GeneCentric Announces “Advances in RNA-based Biomarker Development for Precision Oncology” Webinar Series

This three-part webinar series, “Advances in RNA-based Biomarker Development for Precision Oncology”, will highlight trends in RNA-based biomarker development for precision oncology, ranging from the use of gene expression signatures in the development cancer therapies, to the development of RNA-based companion diagnostics, to novel applications for RNA-based biomarkers in cancer treatment. Part 1 is August 24th, with Parts 2 and 3 September 10th and October 8th.